Related Experiment Video

Updated: Dec 8, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.0K

Immune evasion in renal cell carcinoma: biology, clinical translation, future directions

Xiaoyang Wang1, Robert Lopez2, Rebecca A Luchtel2

  • 1Department of Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, New York, USA.

Kidney International
|September 19, 2020
PubMed

Insights

Renal Cell Carcinoma (RCC) treatments like targeted therapies and immune checkpoint inhibitors show promise, but resistance is common. Understanding immune evasion mechanisms is key to developing effective combination therapies for better patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Renal Cell Carcinoma (RCC) treatment has advanced with targeted therapies and immune checkpoint inhibitors.
  • Despite survival benefits, primary and secondary resistance to these therapies is frequently observed.
  • A deep understanding of RCC's immune evasion strategies is crucial for improving treatment efficacy.

Purpose of the Study:

  • To review the current understanding of immune evasion mechanisms in Renal Cell Carcinoma.
  • To summarize clinical translation of these findings, including ongoing combination trials.
  • To provide perspectives on the future of RCC treatment strategies.

Main Methods:

  • Literature review of mechanisms of immune evasion in RCC.
  • Analysis of clinical trial data for combination therapies involving checkpoint inhibitors.
  • Synthesis of current knowledge and future research directions.

Main Results:

  • RCC cells employ diverse, coordinated mechanisms to evade immune detection and killing.
  • Several clinical trials are investigating combinations of checkpoint inhibitors with other agents.
  • The field is rapidly evolving, with ongoing efforts to overcome resistance.

Conclusions:

  • Overcoming resistance to current RCC therapies requires a thorough understanding of immune evasion.
  • Combination strategies targeting multiple pathways are essential for future treatment success.
  • Continued research into RCC immunology and clinical trials will drive therapeutic advancements.
Keywords:
immune evasionimmunotherapyrenal cancer

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.3K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.0K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K